Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for Alcohol Use Disorder Following Sexual Assault in College Women
The goal of this clinical trial is to determine whether women who engage in heavy drinking with a history of sexual assault (SA) victimization show heightened baseline reactivity to uncertain threat (U-threat), whether alcohol reduces this reactivity and related anxiety, and how these processes link to real-world drinking behavior. The main questions it aims to answer are:
- Test whether heavy drinking women with a history of SA display exaggerated baseline reactivity to U-threat.
- In the lab, test whether alcohol intoxication is associated with decreases in reactivity to U-threat and subjective anxiety, particularly in heavy drinking women with a history of SA.
- In the real-world, test associations between SA victimization, reactivity to U-threat, alcohol consumption, and anxiolytic relief.
Participants will:
- Complete a screening and orientation session
- Complete two experimental lab sessions that will include intravenous (IV) administration of either 80mg% alcohol or placebo (saline), order counterbalanced
- Complete daily ecological momentary assessments (EMA) surveys for 21 days
- Wear a transdermal alcohol wrist biosensor (BACTrack Skyn) for 21-days
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase temprana 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Stephanie Gorka
- Número de teléfono: 614-366-1027
- Correo electrónico: stephanie.gorka@osumc.edu
Ubicaciones de estudio
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Reclutamiento
- Ohio State University
-
Contacto:
- Stephanie Gorka
- Número de teléfono: 614-366-1027
- Correo electrónico: stephanie.gorka@osumc.edu
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
General Inclusion Criteria for All Participants:
- Biological female
- 21-29 years old
- At least a high school education
- Fluency in English
- Heavy drinker as defined as 8 or more alcoholic drinks per week and at least two binge episodes (4 or more drinks for in a 2-hour period) in the past month
Additional Inclusion Criteria for Heavy Drinkers with History of Sexual Assault (HD+SA) Group:
- Self-reported experience of sexual assault victimization after age 14.
Additional Inclusion Criteria for Heavy Drinkers without History of Sexual Assault (HD-SA) Group:
- No exposure to lifetime DSM-5 Criterion A traumatic stressor. Participants will not be excluded for accidents, injuries, or witnessing community violence to ensure the sample is representative.
Exclusion Criteria for All Participants:
- Any serious medical problems (e.g., liver disease, cardiac abnormality, pancreatitis, diabetes, neurological problems, and gastrointestinal disorders)
- Body weight < 110 or > 210 lbs
- Current medical or psychiatric condition requiring medication for which alcohol consumption is contraindicated
- Substance use disorder other than mild and moderate alcohol use disorder
- Positive urine screen for drugs other than cannabis
- Currently seeking or past-12-month history of inpatient or intensive treatment for addictive behaviors
- Pregnancy, nursing, or planning to become pregnant in the next 3 months
- Report smoking more than 5 cigarettes (or electronic equivalent) per day
- Lifetime history of psychosis.
Additional Exclusion Criteria for HD+SA Group:
- Report a first onset SA within the past 30 days
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Otro: Heavy Drinking with a History of Sexual Assault Victimization (HD+SA)
Participants in this group will be required to be biological females between the ages of 21-29 who engage in heavy drinking with a history of sexual assault victimization after age 14. |
Participants receive placebo (saline) intravenously. Participants will receive 80 mg% intravenous alcohol. |
|
Otro: Heavy Drinking without a History of Sexual Assault Victimization (HD-SA)
Participants in this group will be required to be biological females between the ages of 21-29 who engage in heavy drinking either without a history of sexual assault victimization after age 14. |
Participants receive placebo (saline) intravenously. Participants will receive 80 mg% intravenous alcohol. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Startle eyeblink potentiation during the threat task
Periodo de tiempo: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
Startle eyeblink potentiation will be collected during the NPU threat task that is administered at all three lab sessions. Startle is a cross-species index of aversive reactivity. |
Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
|
Subjective affective response to alcohol in the lab
Periodo de tiempo: At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
Participants will complete the Profile of Mood States (POMS) throughout the placebo and alcohol administration protocols. The Profile of Mood States Anxiety subscale consists of 9 items, with each item rated from 0 (not at all) to 4 (extremely), resulting in a total score ranging from 0 to 36. Higher scores indicate greater subjective anxiety, while lower scores indicate less subjective anxiety. The Anxiety subscale will serve as the primary measure of subjective anxiety and will be compared between the placebo and alcohol sessions. |
At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
|
Subjective effects of alcohol in the lab
Periodo de tiempo: At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
Participants will rate the degree to which they 'feel', 'like', and 'want more' of the infused substance on a visual analogue scale ranging from 0 ('not at all') to 100 ('extremely'). The 'like' and 'want more' scales will serve as the primary measures of drug liking and drug wanting, respectively. |
At the Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
|
Ecological momentary assessment (EMA) of affective response to alcohol in the real world
Periodo de tiempo: Assessed daily for 21-days
|
Up to five times per day, participants will complete ecological momentary assessments (EMA) of their current anxiety, distress, and other mood states. Participants will rate each emotion on a 0-5 scale, where 0 = not at all and 5 = extremely. Affect will be assessed during periods of sobriety and intoxication. |
Assessed daily for 21-days
|
|
Transdermal alcohol concentration (TAC)
Periodo de tiempo: Assessed daily for 21-days
|
Participants' TAC will provide an objective estimate of alcohol consumption. |
Assessed daily for 21-days
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2024H0264
- 1R01AA032115-01A1 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified data, including startle eyeblink and behavior, from this project will be submitted to the The National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAADA) at the subject level along with appropriate supporting documentation to enable efficient use of the data by the research community. We will follow instructions as discussed in the NDA Data Sharing Terms and Conditions.
Marco de tiempo para compartir IPD
The data will be submitted biannually.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .